MYALEPT replaces native leptin, a hormone predominantly secreted by adipose tissue that informs the central nervous system (CNS) of the status of energy stores in the body

MYALEPT exerts its function by binding to and activating the human leptin receptor in the hypothalamus. 

Improvements in insulin sensitivity and reductions in food intake are consistent with lower fasting triglyceride, HbA1c, and fasting glucose values that were seen in the MYALEPT clinical trial. Learn more about the MYALEPT clinical trial

MYALEPT is contraindicated in general obesity not associated with congenital leptin deficiency. MYALEPT has not been shown to be effective in treating general obesity. The development of anti-metreleptin neutralizing antibodies have been reported in obese patients treated with MYALEPT.